keverprazan   Click here for help

GtoPdb Ligand ID: 12653

Synonyms: Example 1 [WO2016119505A1] | Keprason®
Approved drug
keverprazan is an approved drug (China (2023))
Compound class: Synthetic organic
Comment: Keverprazan (hydrochloride) is a potassium ion-competitive acid blocker (P-CAB) [3], that was developed to decrease gastric acid production. P-CABs inhibit the gastric H+,K+-ATPase, and are therapeutic alternatives to long-used proton pump inhibitors [4].
P-CABs are an evolving class of drugs, the first of which to enter clinical use was revaprazan in 2007 (S Korea).
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 6
Hydrogen bond donors 1
Rotatable bonds 10
Topological polar surface area 76.25
Molecular weight 432.51
XLogP 1.79
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES CNCC1=CN(C(=C1)C2=C(C=CC=C2)F)S(=O)(=O)C3=CC(=CC=C3)OCCCOC
Isomeric SMILES CNCC1=CN(C(=C1)C2=C(F)C=CC=C2)S(=O)(=O)C3=CC=CC(OCCCOC)=C3
InChI InChI=1S/C22H25FN2O4S/c1-24-15-17-13-22(20-9-3-4-10-21(20)23)25(16-17)30(26,27)19-8-5-7-18(14-19)29-12-6-11-28-2/h3-5,7-10,13-14,16,24H,6,11-12,15H2,1-2H3
InChI Key UDHVRDAZIAGHFG-UHFFFAOYSA-N
References
1. Chen S, Liu D, Chen H, Liao A, Li F, Liu C, Li X, Li S, Zhang Y, Wang Y et al.. (2022)
The efficacy and safety of keverprazan, a novel potassium-competitive acid blocker, in treating erosive oesophagitis: a phase III, randomised, double-blind multicentre study.
Aliment Pharmacol Ther, 55 (12): 1524-1533. [PMID:35505467]
2. Kang C. (2023)
Keverprazan Hydrochloride: First Approval.
Drugs, 83 (7): 639-643. [PMID:37074491]
3. Qin Y, Koh S, Jin Q, Chen T, Jiang J. (2016)
Pyrrole sulfonyl derivative, and preparation method and medical use thereof.
Patent number: WO2016119505A1. Assignee: Jiangsu Kefeiping Medical Co., Ltd., Nanjing Kefeiping Shenghui Pharmaceutical Co., Ltd.. Priority date: 11/11/2015. Publication date: 04/08/2016.
4. Rawla P, Sunkara T, Ofosu A, Gaduputi V. (2018)
Potassium-competitive acid blockers - are they the next generation of proton pump inhibitors?.
World J Gastrointest Pharmacol Ther, 9 (7): 63-68. [PMID:30595950]
5. Tan ND, Liu XW, Liu CX, Li SB, Chen HH, Li X, Wu H, Liao AJ, Zhen YB, Shen PZ et al.. (2022)
Efficacy of keverprazan for duodenal ulcer: A phase II randomized, double-blind, parallel-controlled trial.
J Gastroenterol Hepatol, 37 (11): 2060-2066. [PMID:36068945]